SARS-CoV-2 vaccine strategies in kidney transplant recipients

Prendecki, M.; Willicombe, M.

Prendecki, M.; Willicombe, M..

The Lancet Infectious Diseases ; 23(3):263-264, 2023.

Article in English | EMBASE | ID: covidwho-2276970

Keywords

antibody titer, coronavirus disease 2019/dt [Drug Therapy], coronavirus disease 2019/pc [Prevention], enzyme linked immunospot assay, graft recipient, human, immune response, immunosuppressive treatment, kidney graft, kidney graft rejection/dt [Drug Therapy], kidney graft rejection/pc [Prevention], nonhuman, note, open study, phase 1 clinical trial (topic), plaque reduction neutralization test, randomized controlled trial (topic), repeated drug dose, SARS-CoV-2 Delta, SARS-CoV-2 Omicron, seroconversion, single drug dose, T lymphocyte, treatment response, treatment withdrawal, vaccination, virus neutralization, calcineurin inhibitor/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], elasomeran/do [Drug Dose], elasomeran/dt [Drug Therapy], ibacovavec/dt [Drug Therapy], mycophenolate mofetil/dt [Drug Therapy], tozinameran/do [Drug Dose], tozinameran/dt [Drug Therapy]

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: The Lancet Infectious Diseases Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google